Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04047862
Title	Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	BeiGene
Indications	stomach carcinoma Advanced Solid Tumor lung small cell carcinoma esophagus adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma esophagus squamous cell carcinoma lung non-small cell carcinoma
Therapies	BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab
Age Groups:	adult \| senior
Covered Countries	USA \| NZL \| AUS